BMY is engaged in high-stakes patent actions to defend its top-selling drug, Eliquis, from generics. Simultaneously, it is proactively managing future competition by signing a licensing agreement with Dr. Reddy's Laboratories for an Orencia biosimilar, highlighting a complex legal and competitive strategy to protect key revenue streams.
Filing excerpt
In November 2025, BMS and Pfizer initiated a patent infringement action against an applicant seeking approval to market apixaban products in the U.S.
What this signalsFilings often name leadership changes, deals and spending plans.
Competitors
Regions named
sec-10qlitigationMaterialGet every 10-Q signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/be92cff9-ab25-4e4b-bd40-0559a2b865c4 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.
{
"signal_id": "be92cff9-ab25-4e4b-bd40-0559a2b865c4",
"signal_type": "sec-10q",
"signal_subtype": "litigationMaterial",
"detected_at": "2026-08-04T07:03:39.423+00:00",
"company": {
"name": "Bristol Myers Squibb",
"domain": "bms.com"
},
"data": {
"detail": "BMY is engaged in high-stakes patent actions to defend its top-selling drug, Eliquis, from generics. Simultaneously, it is proactively managing future competition by signing a licensing agreement with Dr. Reddy's Laboratories for an Orencia biosimilar, highlighting a complex legal and competitive strategy to protect key revenue streams.",
"metrics": {
"timeframe": "current_year",
"dollar_context": "Eliquis YTD revenue",
"dollar_millions": 8617
},
"summary": "BMY defends $8.6B drug Eliquis in court and licenses Orencia to competitor Dr. Reddy's",
"excerpts": "In November 2025, BMS and Pfizer initiated a patent infringement action against an applicant seeking approval to market apixaban products in the U.S.",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htm",
"filing_date": "2026-07-30",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/30",
"sales_relevance": "Legal tech opportunity",
"signal_category": "risk",
"regions_mentioned": [
"U.S."
],
"competitors_mentioned": [
"Dr. Reddy's Laboratories"
]
}
}
curl https://signals.autobound.ai/v1/signals/be92cff9-ab25-4e4b-bd40-0559a2b865c4 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.